Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.34 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL750140 | 0.82 | MAPT (0.35) | MAPK14MAPTALDH1A1SMN1; SMN2USP7 | |
| SCHEMBL751631 | 0.80 | TACR1 (0.36) | MAPK14MAPTALDH1A1USP7TSHR | |
| SCHEMBL750351 | 0.79 | USP7 (0.34) | MAPK14MAPTALDH1A1SMN1; SMN2USP7 | |
| SCHEMBL12714509 | 0.77 | TP53 (0.33) | MAPTALDH1A1SMN1; SMN2USP7TSHR | |
| SCHEMBL751894 | 0.74 | USP7 (0.38) | MAPK14MAPTALDH1A1SMN1; SMN2USP7 | |
| SCHEMBL752508 | 0.74 | RIPK3 (0.46) | MAPK14MAPTALDH1A1SMN1; SMN2USP7 | |
| SCHEMBL10273094 | 0.72 | MAPT (0.33) | MAPTALDH1A1SMN1; SMN2USP7MAPK1 | |
| SCHEMBL753472 | 0.71 | RIPK3 (0.39) | MAPK14MAPTUSP7LMNATSHR | |
| SCHEMBL750203 | 0.70 | GRIN1 (0.40) | MAPK14ALDH1A1SMN1; SMN2LMNATSHR | |
| SCHEMBL749861 | 0.70 | TSHR (0.37) | MAPTALDH1A1SMN1; SMN2USP7LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1439174-B1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS AS p38 MAP KINASE INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-21 | — | — | EP | disclosed |
| EP-1628968-B1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-7846933-B2 | such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-7846933-B2 | such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-7846933-B2 | such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | KUBO AKIRA | 2009-04-02 | — | — | US | disclosed |
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | KUBO AKIRA | 2009-04-02 | — | — | US | disclosed |
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | KUBO AKIRA | 2009-04-02 | — | — | US | disclosed |
| US-7473695-B2 | 4-imidazolin-2-one compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-06 | — | — | US | disclosed |
| US-7473695-B2 | 4-imidazolin-2-one compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-06 | — | — | US | disclosed |
| US-7473695-B2 | 4-imidazolin-2-one compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-06 | — | — | US | disclosed |
| EP-1628968-A4 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-03-05 | — | — | EP | disclosed |
| EP-1628968-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004094404-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2004-11-04 | — | — | WO | disclosed |
| US-20040204426-A1 | 4-Imidazolin-2-one compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1439174-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204426-A1 | 4-Imidazolin-2-one compounds | NR3C1, NR3C2, SCN1B | DYRK1B 4022/4885MAPK13 1692/4885MAPK12 1678/4885 |
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | OR10J3, NR4A3, NR3C2 | DYRK1B 3479/4885MAPK13 1997/4885MAPK12 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.